Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P).-Reference-Cited by-同舟云学术

Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P).

Published:2018-05-20 Issue:15_suppl Volume:36 Page:6553-6553
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Zhi Jizu¹,Khozin Sean¹,Kuk Deborah²,Torres Aracelis Z.²,Sorg Rachael²,Lee Shannon E.²,Miksad Rebecca A.²,Pazdur Richard¹,Abernethy Amy Pickar³

Affiliation:

1. U.S. Food and Drug Administration, Silver Spring, MD;

2. Flatiron Health, New York, NY;

3. Duke University Medical Center, Duke Cancer Institute, Durham, NC;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.36.15_suppl.6553

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis;Cancer Biology & Therapy;2024-05-30

2. Body mass index and immune checkpoint inhibitor efficacy in metastatic cancer patients: A Brazilian retrospective study;Frontiers in Urology;2022-12-12

3. The impact of body mass index on overall survival in patients with cancer receiving immunotherapy: a dose-response meta-analysis;Cancer Immunology, Immunotherapy;2022-06-11

4. Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer;Thoracic Cancer;2022-04-08

5. Cancer patients’ constitutional features as a predictor of the efficiency of immunotherapy;Onkologiya. Zhurnal imeni P.A.Gertsena;2022